Figure 6. Anti‐diabetic activity characterization of FGF21^SS .

• A
  FGF21^SS and FGF21 improve insulin resistance by countering the inflammation in 3T3‐L1 adipocytes. Cells were cultured in RAW‐CM to induce inflammation and insulin resistance, while vehicle, FGF21 or FGF21^SS were added simultaneously. The insulin sensitivity was indicated by insulin‐induced AKT phosphorylation using Western blotting analysis. Error bars show the SEM of four independent experiments. *P < 0.05, **P < 0.01 (Student's t‐test) vs. RAW‐CM treated only group.
• B–D
  Anti‐diabetic effect evaluation in ob/ob mice. Mice were injected subcutaneously with vehicle, FGF21 or FGF21^SS at indicated doses every day. Body weight (B) was measured, and plasma glucose (D) was measured every day. Plasma insulin (C) was analyzed at day 7 using insulin ELISA kit. Error bars show the SEM of ten independent experiments. *P < 0.05, **P < 0.01 and ***P < 0.001 (Student's t‐test) vs. vehicle.